Arkema stock gains on higher Q2 2026 earnings

Published on 09/03/2026 at 20:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Arkema stock is backed by improving Q2 2026 earnings and confirmed guidance, while investors watch the specialty chemicals group’s positioning in the CAC Next 20 index and broader European chemicals peer moves.

Flatlay mit Aktienzertifikat, ISIN-Karte und Polymergranulat auf dunklem Untergrund — Flatlay mit ISIN-Karte FR0010313833, Aktienzertifikat und Laborutensilien visualisiert die Kapitalanlage in Arkema S.A. anschaulich, Illustration mit AI erstellt.

Arkema stock (ISIN FR0010313833) is in focus for investors as the French specialty chemicals group reported higher earnings in the second quarter of 2026, with adjusted net profit rising to EUR 129 million from EUR 120 million a year earlier and management reaffirming guidance for slight full year EBITDA growth as of Q1 2026.

Q2 2026 earnings show revenue and profit growth

According to a sector summary of European chemical companies results published on September 3, 2026, Arkema generated Q2 2026 sales of EUR 2.428 billion, up from EUR 2.396 billion in Q2 2025, an increase of about 1.3 percent that highlights modest top line growth in a challenging macro environment.

The same summary reports that Arkema’s Q2 2026 EBITDA came in at EUR 391 million, compared with EUR 364 million in Q2 2025, which means earnings before interest, taxes, depreciation and amortization expanded by roughly 7.4 percent year on year as profitability benefited from Specialty Materials and cost discipline.

Adjusted net profit for Q2 2026 reached EUR 129 million, versus EUR 120 million in the prior year quarter, implying growth of around 7.5 percent and signaling that Arkema is converting revenue and EBITDA improvements into bottom line gains.

Q1 2026 results support full year guidance

An earnings call transcript for Arkema’s Q1 2026 results indicates that the company delivered revenues of EUR 2.2 billion in the first quarter of 2026, down 8.4 percent year on year, while Q1 2026 EBITDA totaled EUR 283 million, which was up 14 percent sequentially but lower compared with the same period of the previous year.

Despite the year on year decline in Q1 2026 revenue, Arkema’s management confirmed guidance for slight full year 2026 EBITDA growth at constant exchange rates, pointing to sequential momentum in Specialty Materials and ongoing cost control as key levers for margin resilience.

For investors, the combination of modest revenue growth in Q2 2026 and expanding EBITDA and adjusted net profit underscores how Arkema is navigating softer demand in some end markets while preserving earnings quality, a central theme in the broader European chemicals sector.

Capital structure and index context

Beyond operating performance, Arkema’s equity structure remains stable. A statement about the number of shares and voting rights published on September 3, 2026 shows that as of August 31, 2026 the company had 76,060,831 shares outstanding and a total of 95,375,484 voting rights including shares held by the company itself, while voting rights excluding treasury shares stood at 94,865,641.

This share and voting rights profile is relevant for institutional investors tracking governance metrics and for index providers, as Arkema is a constituent of Euronext’s CAC Next 20, an index that often serves as a pipeline for potential future additions to the CAC 40 benchmark.

The CAC Next 20 context situates Arkema alongside other mid to large cap French names and helps frame the stock for investors comparing specialty chemicals exposure to the broader Paris market and to DACH peers such as Clariant, which is traded on Germany’s Tradegate platform and provides a regional comparison for valuation and margin trends.

Representative product: specialty additives for mining

Arkema’s operations span adhesives, coatings and advanced materials, but one representative product area for investors is its mining additives portfolio, where the group supplies sulfhydryl collectors under the ArrMaz brand to support copper and cobalt ore processing.

According to a market overview of sulfhydryl collector suppliers dated September 3, 2026, Arkema is listed as a large multinational specialty chemicals provider headquartered in Colombes, France, with its collectors forming part of a broader Specialty Materials offering aimed at critical minerals, an end market that can drive demand for performance additives over the medium term.

Arkema stock and current market perspective

As of September 3, 2026, Arkema stock remains tied to the Paris listing under ISIN FR0010313833, with investors focusing on how the Q2 2026 earnings momentum and confirmed full year 2026 EBITDA guidance translate into share price performance relative to the CAC Next 20 index and European chemicals peers.

The latest figures on revenue and EBITDA growth, combined with stable share and voting rights data as of August 31, 2026, provide a quantitative basis for assessing Arkema’s valuation and leverage profile, even as day to day price moves depend on broader market conditions and sector sentiment.